Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook

Loading...
Loading...
  • Novartis AG NVS has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44.
  • Net income reached $2.2 billion, an increase of 8% or 15% at constant currency rates, mainly driven by higher operating income, partly offset by the loss of Roche Holding RHHBY income.
  • Operating income was $2.85 billion, an increase of 18% from the prior year, mainly due to higher sales, increased productivity, and lower impairments, partly offset by higher R&D and M&S investments.
  • Net sales were $12.53 billion, increasing 1% or 5% at constant currency rates from the prior year, missing the consensus of $12.73 billion.
  • The increase was driven by volume growth of 11 percentage points, price erosion of 3 percentage points, and the negative impact of the generic competition of 3 percentage points.
  • Revenue from Entresto jumped 42% to $1.1 billion.
  • Core operating income at Sandoz returned to growth in the quarter with a gain of 21% to $538 million on a rebound in cold remedies.
  • Guidance: Looking ahead to FY22, Novartis still expects core operating income to grow mid-single digit. Sales are still expected to grow mid-single digit.
  • Price Action: NVS shares are up 0.51% at $90.90 during the premarket session on the last check Tuesday.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...